The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

@article{Nichols2009TheTC,
  title={The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.},
  author={David P Nichols and Assem G. Ziady and Samuel L Shank and Jean F Eastman and Pamela B. Davis},
  journal={American journal of physiology. Lung cellular and molecular physiology},
  year={2009},
  volume={297 5},
  pages={L828-36}
}
Excessive inflammation in cystic fibrosis (CF) lung disease is a contributor to progressive pulmonary decline. Effective and well-tolerated anti-inflammatory therapy may preserve lung function, thereby improving quality and length of life. In this paper, we assess the anti-inflammatory effects of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) in preclinical models of CF airway inflammation. In our experiments, mice carrying the R117H Cftr mutation have… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation

International journal of molecular sciences • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 48 references

The role of inflammation in the pathophysiology of CF lung disease

JF Chmiel, MW Konstan, M. Berger
Clin Rev Allergy Immunol • 2002
View 5 Excerpts
Highly Influenced

CFTR inhibition mimics the cystic fibrosis inflammatory profile.

American journal of physiology. Lung cellular and molecular physiology • 2007
View 2 Excerpts

Similar Papers

Loading similar papers…